Imaging of HER2 with [89Zr]pertuzumab in Response to T-DM1 Therapy.

Imaging of HER2 with [89Zr]pertuzumab in Response to T-DM1 Therapy.

Cancer Biother Radiopharm. 2019 Jan 24;:

Authors: Massicano AVF, Lee S, Crenshaw BK, Aweda TA, El Sayed R, Super I, Bose R, Marquez-Nostra BV, Lapi SE

Abstract
BACKGROUND: The success of human epidermal growth factor receptor 2 (HER2)-targeted therapy depends on accurate characterization of HER2 expression, but current methods available have several limitations. This study aims to investigate the feasibility of [89Zr]pertuzumab imaging to monitor early response to Ado-trastuzumab emtansine (T-DM1) therapy in mice bearing xenografts of HER2-positive breast cancer (BCa).
MATERIALS AND METHODS: Pertuzumab was conjugated to DFO-Bz-NCS and labeled with 89Zr. Mice bearing BT-474 tumors were imaged with [89Zr]pertuzumab and [18F]FDG before and after T-DM1 therapy.
RESULTS: Pertuzumab was successfully labeled with 89Zr with a specific activity of 0.740 MBq/μg. Overall [18F]FDG images showed poor delineation of tumors. Using [18F]FDG-PET to measure tumor volume, the volume remained unchanged from 107.6 ± 20.7 mm3 before treatment to 89.87 ± 66.55 mm3 after treatment. In contrast, [89Zr]pertuzumab images showed good delineation of HER2-positive tumors, allowing accurate detection of changes in tumor volume (from 243.80 ± 40.91 mm3 before treatment to 78.4 ± 40.43 mm3 after treatment).
CONCLUSION: [89Zr]pertuzumab may be an imaging probe for monitoring the response of HER2-positive BCa patients to T-DM1 therapy.

PMID: 30676778 [PubMed - as supplied by publisher]

from A via a.sfakia on Inoreader http://bit.ly/2Dy6FN1